Drug Information

Drug General Information
Drug ID
D00SYV
Former ID
DIB005722
Drug Name
GSK2618960
Indication Multiple scierosis [ICD9: 340; ICD10:G35] Phase 1 [524235]
Company
Glaxosmithkline
Target and Pathway
Target(s) Recombinant human interleukin-7 Target Info Modulator [525001]
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
NetPath Pathway TNFalpha Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Reactome Interleukin-7 signaling
WikiPathways Cytokines and Inflammatory Response
Interleukin-7 signaling
IL-7 Signaling Pathway
References
Ref 524235ClinicalTrials.gov (NCT01808482) A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS). U.S. National Institutes of Health.
Ref 525001ClinicalTrials.gov (NCT02293161) Single Ascending Doses Study of Anti- Interleukin-7 Receptor alpha Monoclonal Antibody (GSK2618960) in Healthy Volunteers. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.